Actively Recruiting
The Efficacy of Intra-articular Triamcinolone Acetonide 5mg vs. 10 mg vs. 40 mg in Patients With Knee Osteoarthritis
Led by Centre hospitalier de l'Université de Montréal (CHUM) · Updated on 2025-02-05
327
Participants Needed
1
Research Sites
106 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Osteoarthritis of the knee is a common problem that is increasing in prevalence as the population ages. In a knee with osteoarthritis, there is variable damage to the articular cartilage and underlying bone that can cause varying degrees of pain. When pain is bothersome, osteoarthritis is treated to improve functional abilities. One of the most recognized and used treatments is intra-articular cortisone injection. Cortisone is a powerful anti-inflammatory drug that is used to reduce pain. Unfortunately, cortisone can have significant side effects, even when injected locally. The frequency and intensity of these side effects depend largely on the total dose injected. The main side effects include increased blood sugar levels, increased blood pressure and a temporary decrease in the secretion of the stress hormone, cortisol. In the long term, a decrease in articular cartilage thickness in the injected join and overall bone density reduction is also reported. Despite many years of routine use, the smallest effective dose of cortisone injected into the knee joint is unknown. The main objective of the study is to determine the impact on pain and function of different doses of cortisone injected into the knee. The cortisone chosen for this study is triamcinolone acetonide (TA).
CONDITIONS
Official Title
The Efficacy of Intra-articular Triamcinolone Acetonide 5mg vs. 10 mg vs. 40 mg in Patients With Knee Osteoarthritis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Symptomatic primary gonarthrosis lasting more than 6 months according to American College of Rheumatology criteria
- Kellgren-Lawrence grade 1 to 3 femorotibial osteoarthritis
- Knee pain during activity rated between 4 and 8 on a 10-point scale
You will not qualify if you...
- Bilateral symptomatic primary gonarthrosis
- Kellgren-Lawrence grade 4 femorotibial osteoarthritis
- Isolated patellofemoral osteoarthritis
- Knee corticosteroid injection within past 3 months or chronic oral corticosteroid use
- Knee hyaluronic acid injection within past 12 months
- Knee platelet-rich plasma injection within past 12 months
- Diseases affecting the study knee such as systemic inflammatory diseases, septic arthritis history, or osteonecrosis
- Suspected or active local infection
- Suspected or known local cancer or metastasis
- Severe knee trauma within past 3 months
- Significant cognitive impairment or language difficulties preventing questionnaire completion
- Any serious medical condition preventing study participation or contraindicating cortisone injection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre Hospitalier Universitaire de Montréal - Hôtel-Dieu
Montreal, Quebec, Canada, H2W 1T8
Actively Recruiting
Research Team
D
Dien Hung Luong, MD
CONTACT
M
Mathieu Boudier-Revéret, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here